Merck and Isomorphic Labs Enter Strategic Research Collaboration
Key Highlights
- ➤Merck and Isomorphic Labs launch oncology small-molecule discovery collaboration
- ➤Merck will handle preclinical, clinical development, manufacturing and commercialization
- ➤Isomorphic Labs receives upfront, milestone payments and tiered net-sales royalties
- ➤Isomorphic Labs can co-fund development for elevated royalties
Expert Statements
George Addona, Senior vice president and head of discovery, preclinical development and translational medicine, Merck Research Laboratories
“The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions.”
George Addona, Senior vice president and head of discovery, preclinical development and translational medicine, Merck Research Laboratories
“By combining Merck’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster.”
Sarah Skerratt, Chief research officer, Isomorphic Labs
“Through this collaboration with Merck, we will apply our world-leading drug design engine to unlock significant discovery progress.”
Sarah Skerratt, Chief research officer, Isomorphic Labs
“By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs.”
Merck and Isomorphic Labs Enter Strategic Research Collaboration
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience.
Get started
Create a free account to read the full story.
